When is Selpercatinib expected to be included in medical insurance reimbursement?

Selpercatinib is a targeted drug used to treat advanced non-small cell lung cancer (NSCLC) and thyroid cancer carrying RET gene mutations. Since Seputinib was approved for marketing in China, it has provided patients with new treatment options. However, the drug is currently not included in China's medical insurance list, so patients need to bear the relevant costs themselves when purchasing it. According to the current market conditions, the price of the original drug of 80mg*56 capsules of Seputinib is expected to exceed RMB 10,000, while the price of the original drug in overseas markets may be as high as tens of thousands to hundreds of thousands of RMB, which makes the cost of using the drug relatively high.

At present, the reason why seputinib has not been included in medical insurance may be related to the particularity of its therapeutic field. Although seputinib has shown good efficacy in areas such as non-small cell lung cancer and thyroid cancer, its indications are relatively limited. Therefore, further clinical data support may be needed for inclusion in China's medical insurance reimbursement, especially its efficacy and economic analysis in practical applications. The medical insurance department needs to evaluate the cost-effectiveness of drugs to ensure that after being included in the medical insurance catalog, the overall medical expenses can be reasonably controlled and more patients can benefit.

In order to reduce the financial burden on patients, generic drugs of seputinib have appeared in foreign markets. Compared with original drugs, generic drugs are more affordable. For example, the generic version of Seputinib produced by a Lao pharmaceutical factory with a specification of 40mg*120 tablets is priced at more than 2,000 yuan. Compared with the high price of the original drug, generic drugs provide patients with a more economical choice. The ingredients of generic drugs are basically the same as those of original drugs, ensuring similar efficacy and safety, and have become the choice of many patients.

At present, there is no clear information on the specific time when seputinib will be included in medical insurance, but with the increase in patient demand and recognition of the drug's efficacy, it is possible that the process of medical insurance reimbursement will be gradually advanced in the next few years. Generally speaking, after a drug is launched in China, the medical insurance department will review it after a period of clinical use and economic evaluation. If the drug's effectiveness and cost-effectiveness are recognized, it may be included in medical insurance, thereby reducing the financial burden on patients.

Reference materials:https://en.wikipedia.org/wiki/Selpercatinib